Opinion on Pharmaceuticals in South and Central America

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

ERS 2010: Daxas and Onbrez add to treatment of COPD

At this year's meeting of the European Respiratory Society, a number of company-sponsored symposia focused on chronic obstructive pulmonary disease, and the fact that mortality from the disease is increasing compared to other chronic diseases. It remains a serious health problem with a global burden. The predominant unmet need is optimized management of the disease.

Published By Datamonitor
07 Oct 2010
Expert View
Expert View

ERS 2010: significant scope for SMART approach

A number of companies used the 2010 meeting of the European Respiratory Society to present new data for asthma treatments. Results from the EuroSMART study highlighted the possibility for use of the Symbicort Maintenance and Reliever Therapy approach across a range of asthmatic patients, while new data for Flutiform and Dulera show promise for these me-too products.

Published By Datamonitor
07 Oct 2010
Expert View
Expert View

ERS 2010: time to look beyond smoking as a cause of COPD

In September, Datamonitor attended this year's European Respiratory Society meeting in Barcelona, Spain. A key issue prevalent at this year's meeting was the global scope of chronic obstructive pulmonary disease and the need to look beyond smoking as a cause. Indeed, data presented at the conference suggest that factors as diverse as air pollution and socioeconomic status play a part.

Published By Datamonitor
07 Oct 2010
Expert View
Expert View

ESMO 2010: Avastin's early success in metastatic ovarian cancer must be confirmed by mature data

At the 2010 European Society of Medical Oncology meeting, Avastin's dominance within the cancer market was strengthened by preliminary positive results from the ICON7 Phase III trial in newly diagnosed ovarian cancer. However, while these results may be enough for a regulatory submission, Avastin's chances of success would be improved greatly if backed up by overall survival data.

Published By Datamonitor
18 Nov 2010
CommentWire
CommentWire

ESMO 2010: cediranib fails pivotal trials leaving Avastin to dominate in colorectal cancer

During the 35th congress of the European Society of Medical Oncology in October, AstraZeneca revealed that its ambitious program to position cediranib as an agent of choice over Avastin in the treatment of first-line metastatic colorectal cancer has failed. Data presented from the Horizon II and Horizon III trials failed to show any meaningful clinical benefit over the control arm of either trial.

Published By Datamonitor
18 Nov 2010
CommentWire
CommentWire

ESMO 2010: GlaxoSmithKline's BRAF inhibitor shows promising early efficacy

In October 2010, Datamonitor attended the 35th congress of the European Society of Medical Oncology, during which results were presented showing that GSK2118436, GlaxoSmithKline's BRAF kinase inhibitor, reduced the overall size of brain metastasis in almost all patients. However, as this success has so far been proved only in early phase trials, GSK must prove this efficacy through mature data.

Published By Datamonitor
18 Nov 2010
Expert View
Expert View

ESMO 2010: PARP inhibitors continue to show promise

At this year's ESMO conference in Milan, Italy, the novel targeted therapy iniparib generated interest in the role of PARP inhibitors in the treatment of cancer. Iniparib has emerged as one of the most promising drugs, after improving survival in triple-negative breast cancer. Many speakers also highlighted the potential for use in other tumor types with BRCA1/BRCA2 mutations.

Published By Datamonitor
18 Nov 2010
Expert View
Expert View

ESMO 2010: Tarceva boosted by positive data

The 35th European Society of Medical Oncology meeting served to showcase two sets of positive results for EGFR-targeted agent Tarceva. In one trial it was shown to improve progression-free survival in the first-line treatment of Stage IIIB/IV non-small cell lung cancer, while in another, early results showed that resistance to Tarceva can be overcome by turning off MET activation with MetMAb.

Published By Datamonitor
18 Nov 2010
Expert View
Expert View

Fast growth MAb market to offer great rewards to a select few over 2009-15

In a new report entitled Monoclonal Antibodies: 2010, Datamonitor predicts that the MAb sector will record a near double-digit growth rate over 2009-15, making it the fastest growing molecule type segment in the prescription pharmaceutical industry. With total sales derived by a select band of blockbuster products, the MAb sector is a tough market to break in to, but one that offers high rewards.

Published By Datamonitor
01 Nov 2010
Expert View
Expert View

FIGO 2009: Bayer-Schering maintains leadership in contraception

Datamonitor attended this year's International Federation of Gynecology and Obstetrics World Congress in Cape Town to assess the state of the women's healthcare market. The overwhelming presence of Bayer-Schering at the conference confirms the company's strength in the contraceptives field and its commitment to maintaining its market-leading position.

Published By Datamonitor
13 Oct 2009

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.